OmniAb Inc. (OABI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$5.23 -0.95% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot)

OmniAb Inc. (OABI) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $760.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510038
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D
Cash (9)Whales (8)SEC (8)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$6 Bull$5 Base$4 Bear
πŸ“¬ FREE OABI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for OABI)Realized 20D OHLCV Swing Band: Β±12.5%
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How OABI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$18.7MGross Profit $9.7M (52%)Cost of Sales $9.0MOp Profit $0 (0%)OpEx (R&D/SG&A) $9.7MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $34.2M
FY24
Rev $26.4M
FY25
Rev $18.7M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$18.7M52%-80%-$64.8M-$37.0M-22.6%
FY 2024$26.4M52%-80%-$62.0M-$41.5M-22.6%
FY 2023$34.2M52%-80%-$50.6M$2.3M-22.6%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OABI)

  • βœ“Walkthrough of OABI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OABI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +276.26%β–² ASCENDING CHANNEL
2026-10-30O $4.40H $5.23L $4.35C $5.23VOL 2.11M
RES: $7.10SUP: $2.50SMA50: $4.65SMA200: $2.70
$5.72$4.53$3.35$2.17$0.98RES $7.10SUP $2.50$5.232026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OABI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -29.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OABI today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for OABI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OABI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OABI)

Health Care Rank #703 of 1016 βš”οΈ NRC vs OABI Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (OABI vs. NRC, ABSI, MXCT, ICLR)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, OmniAb Inc. (OABI) ranks #703 by composite RQD confidence (38/100, grade D-) and #392 by equity capitalization ($760.4M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and β€” gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with OABI at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OABI ACTIVE
OmniAb Inc.
D- 38/100 β€” β€” -22.6% -0.95% $760.4M Benchmark Subject
NRC
NRC Health
C 65/100 44.8x β€” 21.0% +0.09% $519.6M /nrc-vs-oabi β†’
ABSI
Absci Corporation
D 45/100 β€” β€” -35.0% +1.85% $2.08B /absi-vs-oabi β†’
MXCT
MaxCyte Inc.
E 30/100 β€” 96.0% -27.1% +1.17% $178.5M /mxct-vs-oabi β†’
ICLR
ICON plc
B- 71/100 71.9x β€” 3.1% +0.62% $16.50B /iclr-vs-oabi β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001846253

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OmniAb Inc. (OABI) reported GAAP revenue of $18.7M (-29.3% vs. FY2024 revenue of $26.4M , and -45.4% cumulative change since FY2023) , GAAP net income of -$64.8M, operating cash flow of -$36.5M, and free cash flow of -$37.0M (+10.9% YoY). On the balance sheet, OABI closed FY2025 with $300.9M in total assets against $0 in total debt (Altman Z-Score: 12.19, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $18.7M -$64.8M -$36.5M -$37.0M $300.9M β€”
FY2024 (FY) 2024-12-31 $26.4M -$62.0M -$39.7M -$41.5M $325.6M β€”
FY2023 (FY) 2023-12-31 $34.2M -$50.6M $2.3M $2.3M β€” β€”

3. OABI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OABI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, OmniAb Inc. (NASDAQ: OABI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $5.23 (-0.95% 1D, market cap $760.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OABI ranks #703 in composite RQD confidence.

How does OABI compare to NRC and ABSI in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), OABI carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -22.6%. By comparison, NRC (NRC Health) holds a C grade (65/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and ABSI (Absci Corporation) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.08B). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OABI?

Per OABI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001846253), OmniAb Inc. generated $18.7M in revenue (-29.3% YoY), -$64.8M in net income, and -$37.0M in free cash flow against $300.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OABI trading relative to its 50-day, 200-day, and 52-week technical levels?

OABI last traded at $5.23 (-0.95% on volume of 1,683,619 shares), positioning the stock +12.47% above its 50-day simple moving average ($4.65) and +93.70% above its 200-day simple moving average ($2.70). Across its 52-week range of $1.30 to $5.43, OABI sits at the 95.2% percentile with a 14-day RSI of 58.7 (BULLISH MOMENTUM) and an implied next-earnings move of Β±12.5% ($4.58 to $5.88).

OABI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

How profitable is OmniAb Inc. (OABI)?

In FY 2025 (10-K), OABI converted $18.7M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%